FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	3,	
STATEMENT OF CHANGES IN RENEFICIAL OWNERSHIP		
	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP

	PROVAL
OMB Number:	3235-0287
Estimated average	hurden

Check this box if no longer subject to Section 16. Form 4 or Form 5

44 MONTGOMERY STREET

 $\mathbf{C}\mathbf{A}$

(State)

1. Name and Address of Reporting Person*

94104

(Zip)

40TH FLOOR

FRANCISCO

(Street) SAN

(City)

UIVID AP	PROVAL
OMB Number:	3235-0287
Estimated averag	e burden
hours per respons	se: 0.5

U obligat	tion 10.1 offine tions may conf ction 1(b).			Filed	l pursuar or Sec	nt to S	ection	16(a) of the Ir	of the S	ecurit	ies Exchange	Act of 1940	1934	1		hours	per re	sponse:	0).5
1. Name and Address of Reporting Person* 2. Is					2. Issu	or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Repare Therapeutics Inc. [RPTX]								5. Relationship of Re (Check all applicable Director		licable)			Issuer Owner	
(Last) 44 MON 40TH FI	TGOMER	irst) (I Y STREET	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/18/2022						Office below	er (give title /)		Other (below)	(specify					
(Street) SAN FRANCI	ISCO C	A 9	4104		4. If A	mendr	ment,	Date o	f Origina	al File	d (Month/Day	/Year)		6. Indi Line)	Form	· Joint/Grou filed by On filed by Mo on	e Rep	orting Pers	son	е
(City)	(S	tate) (2	Zip)																	
		Table	I - No	n-Deriva	ative S	ecur	rities	Acq	uired,	Dis	posed of,	or B	enet	ficially	/ Own	ed				
1. Title of S	Security (Ins	str. 3)		2. Transac Date (Month/Da	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Ac Disposed Of (D) 5)					and Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) c (D)	or P	Price	Report Transa (Instr. 3	ction(s) 3 and 4)			(Instr. 4	
Common	Shares, no	par value ⁽¹⁾		05/18/	2022				P		224,388	A		\$8.5	3,3	50,950		D ⁽²⁾		_
		par value ⁽¹⁾		05/18/					P		189,882	A		\$8.5	 	05,507		D ⁽³⁾		_
Common	Shares, no	par value ⁽¹⁾		05/18/		<u> </u>			P		5,730	A		\$8.5	<u> </u>	3,357		D ⁽⁴⁾		
		Ta									osed of, convertible				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	emed ion Date, /Day/Year)	4. Transac Code (li 8)		of Deriv Secu Acqu (A) o Dispo	r osed) r. 3, 4	toer of Expiration Date (Month/Day/Year) Ged of Month/Day/Year) 7. Title an Amount of Securities Underlyin Derivative Security (3 and 4)		nt of ties lying tive ty (Ins	De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Benef Owne (Instr.	irect icial rship		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date		Amou or Numb of Share	ber						
		of Reporting Person*																		
(Last) 44 MON 40TH FI		(First) Y STREET	(Mi	ddle)																
(Street) SAN FRANCI	ISCO	CA	94	104																
(City)		(State)	(Zip	p)																
		of Reporting Person* OGY VALUE	E FUN	ND L P																
(Last)		(First)	(Mi	ddle)																

(Last)	(First)	(Middle)
	ERY ST., 40TH FI	
,	,	-
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
Name and Addres	s of Reporting Person	n*
	· -	 <u>JE FUND II LP</u>
(Last)	(First)	(Middle)
44 MONTGOMI	ERY STREET	
40TH FLOOR		
(Street)		
SAN	CA	94104
FRANCISCO	U.1.) IIV I
(City)	(State)	(Zip)
1. Name and Addres BVF II GP LI	s of Reporting Person	n
, vr ii Ur Li		
(Last)	(First)	(Middle)
	ERY ST., 40TH FI	
(Street)		
SAN FRANCISCO	CA	94104
TRANCISCO		
(City)	(State)	(Zip)
1. Name and Addres	s of Reporting Person	n [*]
1. Name and Addres	s of Reporting Person	n [*]
1. Name and Address Biotechnolog (Last)	s of Reporting Person <u>y Value Tradin</u>	g Fund OS LP
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U	is of Reporting Person Y Value Tradin (First)	g Fund OS LP
1. Name and Address Biotechnolog (Last)	is of Reporting Person y Value Tradin (First) GLAND HOUSE	g Fund OS LP (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U	is of Reporting Person Y Value Tradin (First)	g Fund OS LP
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN	is of Reporting Person y Value Tradin (First) GLAND HOUSE	(Middle) KY1-1104
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND	is of Reporting Person y Value Tradin (First) GLAND HOUSE	g Fund OS LP (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State)	(Middle) KY1-1104 (Zip)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State)	(Middle) KY1-1104 (Zip)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd.	(Middle) KY1-1104 (Zip)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State)	(Middle) KY1-1104 (Zip) n* (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First)	(Middle) KY1-1104 (Zip) n* (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First)	(Middle) KY1-1104 (Zip) n* (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street) GRAND	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First)	(Middle) KY1-1104 (Zip) n* (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE	(Middle) KY1-1104 (Zip) n* (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street) GRAND	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE	(Middle) KY1-1104 (Zip) n* (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) (City)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip)
1. Name and Address Biotechnology (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Address	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip)
1. Name and Address Biotechnology (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Address BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Address	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE E9 (State) is of Reporting Person is of Reporting Person	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U Street) GRAND CAYMAN (City) 1. Name and Addres BVF GP HOI (Last)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE E9 (State) is of Reporting Person DINGS LLC	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip) (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U Street) GRAND CAYMAN (City) 1. Name and Addres BVF GP HOI (Last)	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE E9 (State) is of Reporting Person is of Reporting Person Country (First) is of Reporting Person Country (First)	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip) (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF GP HOI (Last) 44 MONTGOMI	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE E9 (State) is of Reporting Person is of Reporting Person Country (First) is of Reporting Person Country (First)	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip) (Middle)
1. Name and Addres Biotechnolog (Last) P.O. BOX 309 U Street) GRAND CAYMAN (City) 1. Name and Addres BVF Partners (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addres BVF GP HOI (Last) 44 MONTGOMI	is of Reporting Person y Value Tradin (First) GLAND HOUSE E9 (State) is of Reporting Person OS Ltd. (First) GLAND HOUSE E9 (State) is of Reporting Person is of Reporting Person Country (First) is of Reporting Person Country (First)	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip) (Middle)

(City)	(State)	(Zip)
1. Name and Address BVF INC/IL	of Reporting Person*	
(Last)	(First)	(Middle)
44 MONTGOMEI	RY STREET	
40TH FLOOR		
(Street) SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address LAMPERT MA		
(Last)	(First)	(Middle)
44 MONTGOMEI	RY STREET	
40TH FLOOR		
(Street) SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)

Explanation of Responses

- 1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively beneficially owns over 10% of the Issuer's outstanding Common Shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- 2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially the own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- 3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- 4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/20/2022
Biotechnology Value Fund, L.P., By: BVF Partners L.P., its investment manager, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/20/2022
BVF I GP LLC, By: BVF GP Holdings LLC, its sole member, By: /s/ Mark N. Lampert, Chief Executive Officer	05/20/2022
Biotechnology Value Fund II, L.P., By: BVF Partners L.P., its investment manager, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/20/2022
BVF II GP LLC, By; BVF GP Holdings LLC, its sole member, By; /s/ Mark N. Lampert, Chief Executive Officer	05/20/2022
BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/20/2022
Biotechnology Value Trading Fund OS LP, By; BVF Partners L.P., its investment	05/20/2022

manager, BVF Inc., its general partner, By: /s/ Mark N.
Lampert, President

BVF GP Holdings LLC, By:

/s/ Mark N. Lampert, Chief 05/20/2022

Executive Officer

BVF Inc., By: /s/ Mark N. 05/20/2022

<u>Lampert, President</u>
/s/ Mark N. Lampert

05/20/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.